A Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo When Administered in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Breast Cancer
Latest Information Update: 05 Dec 2022
At a glance
- Drugs Sorafenib (Primary) ; Paclitaxel
- Indications Adenocarcinoma; Advanced breast cancer
- Focus Therapeutic Use
- Acronyms TIES
- 01 May 2019 Status changed from completed to active, no longer recruiting.
- 01 May 2019 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.
- 01 May 2019 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2020.